Febhuwari 2024: Several new drugs and promising therapies, such as chimeric antigen receptor T-cell therapy, have ushered in a “renaissance” for lupus, according to a speaker at the symposium Basic and Clinical Immunology for the Busy Clinician.
According to Emily Littlejohn, DO, MPH, of the Cleveland Clinic, monoclonal antibodies and interferons are two additional potential treatments for systemic lupus erythematosus that have emerged since 2020.
“2020 is what many of us consider the lupus renaissance,” Littlejohn told attendees during the hybrid meeting. “This is a time where, finally, we had many drugs entering the armamentarium very quickly.”
Ungahle uthande ukufunda: I-CAR T Cell therapy eShayina
According to Littlejohn, there have been a lot of exciting new treatments for SLE since the quick approvals of belimumab (Benlysta, GSK), voclosporin (Lupkynis, Aurinia), and anifrolumab (Saphnelo, AstraZeneca). CAR T-cell therapy might be the most exciting of these.
“This is used in the oncology world—we have seen it in [B-cell acute lymphoblastic leukemia], [B-cell non-Hodgkin’s lymphoma] and mantel cell lymphoma,” Littlejohn said. “The question is: What about in our diseases?”
U-Littlejohn uthe zonke iziguli ezibambe iqhaza ocwaningweni lwaseJalimane olwabhalisa iziguli ezinhlanu ezinokubandakanyeka kwezitho eziningi zakwazi ukufeza isimo lapho i-nephritis yaphela khona. U-Littlejohn wengeze ngokuthi imiphumela inikeza ithemba, kodwa ukwelashwa akunabungozi.
Ungahle uthande ukufunda: I-CAR T Cell therapy ye-myeloma eminingi e-China
"Kunengozi enkulu ye-cytokine release syndrome - ikakhulukazi i-ICANS - eyethusa kakhulu," kusho yena.
“Ngicabanga ukuthi kunezithembiso eziningi kulesi sikhala, uma nje ngicabangela lezi ziguli ezinhlanu [ezelashwe nge-CAR-T cell therapy] nokuthi zenze kahle kangakanani,” wengeza.
Ezinye izindlela zokuthi Ukwelashwa kwe-CAR T-cell are in development. These include litifilimab (BIIB059, Biogen), interferon—kinoid, obinutuzumab (Gazyva, Genentech) and iberdomide (Bristol Myers Squibb).
I-Interferon–kinoid yehlulekile ukuhlangabezana neziphetho ezivivinyweni ezibalulekile, futhi ikusasa layo “aliqinisekile,” kusho uLittlejohn.
Ungahle uthande ukufunda: Izindleko zokwelashwa kwamaseli e-CAR T e-China
"I-Litifilimab yaqale yafundwa ezigulini ze-cutaneous lupus, isamba esingu-132," kusho uLittlejohn. "Abakuthola ukuthi ihlangabezane neziphetho eziyinhloko ngokuncipha kwesibalo sesikhumba se-CLASI ngeviki le-16."
Ukwengeza, umuthi uphumelele ekwehliseni inani lamalunga esifo esisebenzayo, ngokusho kukaLittlejohn.
Ekugcineni, i-obinutuzumab ihlangabezane nesiphetho sayo esiyinhloko ezigulini ezine-lupus nephritis, kusho uLittlejohn.
